Metal Aluminum Nano-Adjuvant for Enhanced Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Traditional aluminum salt adjuvants, such as aluminum hydroxide, have low induction efficiency for cellular immune responses and limited antigenic storage effects, leading to suboptimal immune stimulation in vaccines.
Innovation Solution
Development of metal aluminum nano-adjuvants with controllable size and monodisperse particle distribution, prepared using methods like electric explosion or ligand regulation, to enhance humoral and cellular immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional aluminum hydroxide adjuvant is used, then antigen adsorption is achieved, but the induction efficiency for cellular immune response is low
Solution Approach 1:
The patent segments the conventional aluminum hydroxide adjuvant into nanoscale particles (10-100 nm), creating metal aluminum nanoparticles that exhibit enhanced immunogenicity. This segmentation increases the surface area to volume ratio, improving antigen adsorption capacity and cellular uptake efficiency, thereby resolving the contradiction between reliability and productivity in immune response induction.
Solution Approach 2:
The patent changes the critical parameter of particle size from micrometer scale (conventional aluminum hydroxide) to nanometer scale (metal aluminum nanoparticles). This parameter change fundamentally alters the immunological properties, enabling efficient induction of both humoral and cellular immune responses while maintaining antigen adsorption capabilities.
2Quantity of substance
If aluminum salt adjuvant is used, then antigenic storage is provided, but the antigenic storage effect is limited
Solution Approach 1:
The patent utilizes the porous surface structure of metal aluminum nanoparticles to enhance antigenic storage capacity. The nanoscale porosity provides increased surface area and multiple binding sites for antigen molecules, allowing higher antigen loading while maintaining stable storage and controlled release, thus resolving the contradiction between quantity and reliability of antigenic storage.
3Ease of manufacture
If conventional aluminum adjuvant is used, then vaccine preparation is simplified, but safety issues arise with local reactions at injection site
Solution Approach 1:
The patent changes the particle size parameter to nanoscale dimensions, which fundamentally improves the safety profile of the adjuvant. The small nanoscale particles exhibit reduced reactivity and lower incidence of local reactions at injection sites compared to conventional micrometer-scale aluminum adjuvants, while maintaining ease of vaccine preparation through similar formulation processes.
4Reliability
If aluminum hydroxide gel adjuvant is used, then strong immunity is achieved, but it is only suitable for vaccines with strong immunity or large quantity production
Solution Approach 1:
The patent creates a universal nanoscale metal aluminum adjuvant platform that can effectively enhance both humoral and cellular immune responses. This multi-functional adjuvant is adaptable to various vaccine types including peptide vaccines, protein vaccines, and therapeutic vaccines, resolving the limitation of conventional aluminum adjuvants that are only suitable for specific vaccine formulations or large-scale production.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The metal aluminum nano-adjuvants significantly improve immune response induction, offering better safety and efficacy compared to conventional adjuvants, making them suitable for both preventive and therapeutic vaccines.
Implementation Method 1
aluminum salt adjuvant has been used as vaccine adjuvant for more than 90 years, and it is the first adjuvant approved by the US Food and Drug Administration (FDA) for human vaccine
Data Source
AI summary
Disclosed are a metal aluminum nano-adjuvant, a vaccine composition and a preparation method therefor and a use thereof. The vaccine adjuvant comprises metal aluminum nanoparticles, and can be used as a candidate adjuvant for preventive vaccines and therapeutic vaccines for various diseases such as infections, autoimmune diseases and tumors. The combined use of the vaccine adjuvant provided by the present disclosure and antigen can effectively enhance the humoral immune response and the cellular immune response of the vaccine, and the enhancement effect is significantly better than that of the commercially available aluminum hydroxide adjuvant.